Modulation of Muscle Protein Metabolism by Essential Amino Acids (Aj1B)

January 16, 2014 updated by: University of Nottingham
The investigators plan to explore the ability of amino acids, the building blocks of proteins in our bodies and in the food we eat, to stimulate muscles to grow and stay strong. The investigators will investigate how rapidly after one meal the human body is ready to make use of a second meal and look at the molecular mechanisms underlying this. The investigators will look at these phenomena in older men as this group is known to be subject to a gradual loss of muscle mass and strength.

Study Overview

Detailed Description

Muscles can stay very constant in size for much of adult life yet dramatic wasting is seen in advanced age and ill health. A better understanding of how muscles regulate their size will help design treatments to slow wasting in disease and to promote active aging. We plan to study a group of older men, ~70yrs, the age at which muscle bulk starts to decrease, to observe how the muscles respond to feeding. We will provide a drink that contains the digested products of proteins from which muscles are built. Taking blood samples and some tiny biopsies of muscle (done under local anaesthesia) will allow us to measure muscle turnover and we will be able to measure for how long after a meal muscles actively take in nutrients before becoming "full". We will also measure how long the muscle remains "full" before it returns to a state where it can again be stimulated to take in nutrients. We will also explore if leucine, one of the component parts of protein (especially in meat and dairy products) and a food widely used supplement, can promote the early re-stimulation of muscle by eating.

Study Type

Interventional

Enrollment (Anticipated)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Derby, United Kingdom, DE22 3DT
        • Recruiting
        • School of Graduate Entry Medicine
        • Contact:
        • Sub-Investigator:
          • William K Mitchell, MA MB BChir
        • Principal Investigator:
          • Philip J Atherton, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 75 years (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male
  • 65-75yrs
  • BMI 18-28

Exclusion Criteria:

  • Type 2 Diabetes mellitus
  • Neurological Disease
  • Significant cardiac, hepatic or renal disease
  • Active malignancy
  • Medication inc. Corticosteroids, NSAID use, Beta adrenoblockers.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Early leucine refeed
15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
Dissolved in 250ml water.
Dissolved in 250ml water.
Experimental: Early EAA refeed
15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Dissolved in 250ml water.
Experimental: Mid latency EAA refeed
15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Dissolved in 250ml water.
Experimental: Late latency EAA refeed
15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
Dissolved in 250ml water.
Dissolved in 250ml water.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myofibrillar Fractional Synthetic Rate
Time Frame: 6-10hrs
Assessed by gas-chromatography-combustion-mass spectrometry, using incorporation of a stable isotope tracer (13-C-6 Phe)
6-10hrs

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Leg blood flow
Time Frame: 6-10hrs
Common femoral bulk flow (Doppler USS)
6-10hrs
mTORC1 and AKT phosphorylation
Time Frame: 6-10hrs
Western Immunoblotting
6-10hrs
Muscle Protein Breakdown
Time Frame: 6-10hrs
By Arteriovenous limb balance
6-10hrs

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Philip J Atherton, PhD, University of Nottingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2013

Primary Completion (Anticipated)

June 1, 2014

Study Completion (Anticipated)

July 1, 2014

Study Registration Dates

First Submitted

June 26, 2013

First Submitted That Met QC Criteria

June 28, 2013

First Posted (Estimate)

July 1, 2013

Study Record Updates

Last Update Posted (Estimate)

January 17, 2014

Last Update Submitted That Met QC Criteria

January 16, 2014

Last Verified

January 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • B13122012 GEM BMS

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Old Age

Clinical Trials on 15g Mixed Essential Amino Acids

Subscribe